111 related articles for article (PubMed ID: 25449528)
1. Chemotherapy of WAP-T mouse mammary carcinomas aggravates tumor phenotype and enhances tumor cell dissemination.
Jannasch K; Wegwitz F; Lenfert E; Maenz C; Deppert W; Alves F
Int J Cancer; 2015 Jul; 137(1):25-36. PubMed ID: 25449528
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells.
Maenz C; Lenfert E; Pantel K; Schumacher U; Deppert W; Wegwitz F
BMC Cancer; 2015 Mar; 15():178. PubMed ID: 25886487
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice.
Lenfert E; Maenz C; Heinlein C; Jannasch K; Schumacher U; Pantel K; Tolstonog GV; Deppert W; Wegwitz F
Int J Cancer; 2015 Mar; 136(6):E521-33. PubMed ID: 25195563
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect reflected by plasma levels of a viral protein during combination chemotherapeutic treatment of mammary tumor-bearing mice.
Ritzi EM; Martin DS; Stolfi RL; Spiegelman S
Cancer Res; 1985 Nov; 45(11 Pt 1):5374-8. PubMed ID: 3840411
[TBL] [Abstract][Full Text] [Related]
5. [The in vitro combination-effect of toremifene with CAF (cyclophosphamide, adriamycin, 5-fluorouracil) on growth of various human mammary carcinomas].
Kuroiwa S; Maruyama S; Okada M; Abe F
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1581-9. PubMed ID: 9725052
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of a viral protein during adjuvant treatment: reflection of murine mammary tumor status and therapeutic effect.
Ritzi EM; Martin DS; Stolfi RL
Cancer Res; 1986 Jun; 46(6):2804-9. PubMed ID: 3754489
[TBL] [Abstract][Full Text] [Related]
7. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
[TBL] [Abstract][Full Text] [Related]
8. [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
Abe O; Izuo M; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
Gan To Kagaku Ryoho; 1982 May; 9(5):866-73. PubMed ID: 7184431
[TBL] [Abstract][Full Text] [Related]
9. Levels of viral glycoprotein reflect enhanced effectiveness of combined drug treatments.
Ritzi EM; Pyo S
Life Sci; 1994; 54(13):887-99. PubMed ID: 8139377
[TBL] [Abstract][Full Text] [Related]
10. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Saeki T; Nomizu T; Toi M; Ito Y; Noguchi S; Kobayashi T; Asaga T; Minami H; Yamamoto N; Aogi K; Ikeda T; Ohashi Y; Sato W; Tsuruo T
J Clin Oncol; 2007 Feb; 25(4):411-7. PubMed ID: 17179098
[TBL] [Abstract][Full Text] [Related]
11. [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
Taguchi T; Sakai K; Terasawa T; Wada H
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2820-8. PubMed ID: 3530139
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
14. In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer.
McCarthy M; Auda G; Agrawal S; Taylor A; Backstrom Z; Mondal D; Moroz K; Dash S
Exp Mol Pathol; 2014 Aug; 97(1):6-15. PubMed ID: 24780744
[TBL] [Abstract][Full Text] [Related]
15. Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression.
Otto B; Gruner K; Heinlein C; Wegwitz F; Nollau P; Ylstra B; Pantel K; Schumacher U; Baumbusch LO; Martin-Subero JI; Siebert R; Wagener C; Streichert T; Deppert W; Tolstonog GV
Int J Cancer; 2013 Mar; 132(6):1300-10. PubMed ID: 22907219
[TBL] [Abstract][Full Text] [Related]
16. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
17. Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Zhang SH; Zhang H; He HW; Li L; Li XQ; Zhang YP; Shao RG
Cancer Chemother Pharmacol; 2013 Oct; 72(4):777-88. PubMed ID: 23975242
[TBL] [Abstract][Full Text] [Related]
18. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
[TBL] [Abstract][Full Text] [Related]
19. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of adriamycin for advanced breast cancer (3)--a joint study by 26 institutes on the CAF and CMcF treatment].
Kubo K; Abe O; Izuo M; Enomoto K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
Gan To Kagaku Ryoho; 1983 Dec; 10(12):2523-31. PubMed ID: 6689117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
